Vivjoa (oteseconazole) — Highmark

reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are not of reproductive potential

Initial criteria

Diagnosis of recurrent vulvovaginal candidiasis (RVVC)
Member has experienced ≥ 3 episodes of vulvovaginal candidiasis (VVC) in less than one year
Prescriber attests that the member is not of reproductive potential defined as one of the following: postmenopausal OR another reason for permanent infertility (e.g., tubal ligation, hysterectomy, salpingo-oophorectomy)
Member has experienced therapeutic failure, contraindication, or intolerance to a six-month maintenance course of oral fluconazole

13 weeks